Polyglutamine diseases: emerging concepts in pathogenesis and therapy.
Polyglutamine diseases are a family of neurodegenerative conditions that each derive from a CAG triplet repeat expansion in a specific gene. This produces a pathogenic protein that contains a critically expanded tract of glutamines. These prototypical protein misfolding disorders include Huntington disease, spinobulbar muscular atrophy, dentatorubral-pallidoluysian atrophy and several spinocerebellar ataxias. This article reviews the emerging concepts in pathogenesis and therapy. Key ideas include the role of proteolytic cleavage, the importance of conformational change in the pathogenic proteins, the role of protein aggregation and the importance of transcriptional and metabolic disturbances. The relative role of functional perturbation in a target protein induced by a polyglutamine expansion is also discussed. Therapeutic strategies include counteracting cellular perturbations and direct targeting of polyglutamine protein expression, cleavage or conformation.
Shao
Jieya
J
Department of Neurology, UCSF, San Francisco, CA 94143, USA.
Diamond
Marc I
MI
D015316:Genetic Therapy; D020271:Heredodegenerative Disorders, Nervous System / Q000209:etiology* / Q000235:genetics / Q000628:therapy*; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D010455:Peptides / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D011487:Protein Conformation; D014158:Transcription, Genetic; D019680:Trinucleotide Repeat Expansion
D010455:Peptides; C097188:polyglutamine; D010447:Peptide Hydrolases